Analysis of 7,500 patients showed one-third had potentially actionable mutations and 10 percent were misdiagnosed, prompting calls for greater NGS use in this setting.
Circulating Tumor Cells Could Be Key to Noninvasive PD-L1 Tracking in Small Cell Lung Cancer
Premium
Early research suggests size-based sorting of circulating tumor cells may open new avenues for blood-based PD-L1 expression analysis in SCLC patients.
The agency had originally planned to delete unspecified diagnosis codes for certain cancer tests covered under a national coverage decision.
Novartis Nets Tumor-Agnostic Approval for Tafinlar-Mekinist Combo
The accelerated approval makes the combination available to patients with any refractory tumor harboring a BRAF V600E mutation, except for those with colorectal cancer.
MD Anderson Study Explains Differing BRAF/MEK Treatment Responses in Male, Female Melanoma Patients
Premium
If validated, the findings could inform strategies for improving responses to BRAF/MEK inhibitors including using androgen receptor blockers.
BMS Submits Breyanzi for European Approval as Second-Line Lymphoma Treatment
The CAR T-cell therapy is already approved in Europe as a third-line treatment for relapsed or refractory large B-cell lymphoma.